Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

ValueAct Still Believes Strongly in Microsoft Corporation (MSFT): Here’s Why

Page 1 of 4

In a Form 4 filing with the SEC yesterday, Jeffrey Ubben’s ValueAct Capital disclosed seven purchases of Microsoft Corporation (NASDAQ:MSFT) stock between February 2 and February 4, totaling slightly over 1 million shares. The purchases increased their position in Microsoft, which has long been their most valuable holding, to 67.9 million shares.


Ubben co-founded ValueAct in 2000, and has been both its CEO and Chief Investment Officer ever since. The activist fund manages a small portfolio of valuable, long-term positions in companies it feels are undervalued, taking large ownership stakes and using its position to constructively work with the boards and upper management of those companies to affect positive change.

Their strategy of focused activist investing has proven extremely successful, and forms some of the foundation for our own investing principles. ValueAct’s 13F positions returned an average of 1.29% per month between 2002 and 2012. The S&P 500 Index returned an average of 0.47% per month during the same period. All investors had to do was blindly imitate Ubben’s stock picks to outperform the market by 10 percentage points per year. This performance is even better than Warren Buffett‘s returns during the same period.

In early 2013, coming off that exceptional 11-year run, ValueAct made their move into Microsoft Corporation (NASDAQ:MSFT), purchasing 33.35 million shares of the legendary, but stagnating (at least stock-wise) software maker in the first quarter of 2013, and building that up to 57.75 million shares in the second quarter, a $2 billion investment all told. It was a bold and even contrarian move for the fund, who seemed out-to-lunch on any plans of activist investing in the giant company; even their $2 billion investment only amounted to a 1% stake.

Even aside from that, the stock itself was not particularly attractive, at least to the average analyst and investor. David Einhorn targeted Microsoft at the 2011 Ira Sohn Conference but that went nowhere (read transcript of Einhorn’s presentation). It had tread water for the past decade under the guidance of Steve Ballmer, whose leadership it was rumored ValueAct was concerned about. Yet as contrarian as the move seemed in many ways, ValueAct also summed up their investment succinctly when discussing it in their First Quarter 2013 Report, where it was their Featured Investment:

Some of our most successful investments over the years have been in situations where other investors can’t seem to shed their past perceptions of the company’s prospects.

Page 1 of 4

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!